See more : MSG Networks Inc. (MSGN) Income Statement Analysis – Financial Results
Complete financial analysis of Biodesix, Inc. (BDSX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biodesix, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- MONIND LIMITED (MONIND.BO) Income Statement Analysis – Financial Results
- Almaden Minerals Ltd. (AAU) Income Statement Analysis – Financial Results
- Kepler Weber S.A. (KEPL3.SA) Income Statement Analysis – Financial Results
- Fortum Oyj (FOJCF) Income Statement Analysis – Financial Results
- The Planting Hope Company Inc. (MYLK.V) Income Statement Analysis – Financial Results
Biodesix, Inc. (BDSX)
About Biodesix, Inc.
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 49.09M | 38.21M | 54.51M | 45.56M | 24.55M | 20.43M |
| Cost of Revenue | 13.01M | 14.15M | 30.52M | 22.00M | 6.07M | 4.41M |
| Gross Profit | 36.08M | 24.06M | 23.99M | 23.56M | 18.48M | 16.03M |
| Gross Profit Ratio | 73.50% | 62.96% | 44.01% | 51.71% | 75.26% | 78.44% |
| Research & Development | 9.99M | 13.10M | 12.79M | 10.82M | 10.47M | 8.19M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 30.64M | 25.90M |
| Selling & Marketing | 0.00 | 61.46M | 50.52M | 34.86M | 30.64M | 25.90M |
| SG&A | 67.39M | 61.46M | 50.52M | 34.86M | 30.64M | 25.90M |
| Other Expenses | 44.00K | 109.00K | -9.00K | 422.00K | -2.38M | -1.24M |
| Operating Expenses | 77.42M | 74.56M | 63.31M | 45.68M | 41.11M | 34.09M |
| Cost & Expenses | 90.43M | 88.72M | 93.82M | 67.67M | 47.18M | 38.49M |
| Interest Income | 0.00 | 8.07M | 4.51M | 18.00K | 55.00K | 24.00K |
| Interest Expense | 9.54M | 8.07M | 4.51M | 7.60M | 3.01M | 2.92M |
| Depreciation & Amortization | 5.51M | 3.60M | 3.18M | 2.90M | 2.79M | 1.74M |
| EBITDA | -37.10M | -53.78M | -35.47M | -20.84M | -24.93M | -21.51M |
| EBITDA Ratio | -75.59% | -131.89% | -72.15% | -47.58% | -90.25% | -85.81% |
| Operating Income | -41.34M | -50.51M | -39.32M | -22.12M | -22.63M | -23.46M |
| Operating Income Ratio | -84.22% | -132.17% | -72.14% | -48.55% | -92.16% | -114.82% |
| Total Other Income/Expenses | -10.80M | -14.86M | -2.22M | -8.42M | -3.99M | -2.71M |
| Income Before Tax | -52.15M | -65.45M | -43.16M | -31.35M | -30.73M | -26.17M |
| Income Before Tax Ratio | -106.23% | -171.27% | -79.18% | -68.81% | -125.15% | -128.06% |
| Income Tax Expense | 0.00 | 14.94M | 1.32M | 5.12M | 629.00K | 211.00K |
| Net Income | -52.15M | -80.39M | -44.48M | -36.47M | -31.36M | -26.17M |
| Net Income Ratio | -106.23% | -210.37% | -81.61% | -80.06% | -127.71% | -128.06% |
| EPS | -0.64 | -1.91 | -1.63 | -1.37 | -1.23 | -0.99 |
| EPS Diluted | -0.64 | -1.91 | -1.63 | -1.37 | -1.23 | -0.99 |
| Weighted Avg Shares Out | 82.11M | 42.10M | 27.37M | 26.56M | 25.49M | 26.54M |
| Weighted Avg Shares Out (Dil) | 82.11M | 42.10M | 27.37M | 26.56M | 25.49M | 26.54M |
Biodesix Named to Inc. Magazine's 2024 “Best Workplaces”
Biodesix to Participate in Two Investor Conferences in June
Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting
Biodesix, Inc. (BDSX) Q1 2024 Earnings Call Transcript
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference
Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024
Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement
Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center
Source: https://incomestatements.info
Category: Stock Reports